Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03424382 · ClinicalTrials.gov registry record
CREATION Health Readmission Risk Assessment Tool
A clinical trial, sponsored by AdventHealth.
- Completed
- Registry status
- 1,218
- Enrollment target
NCT03424382: Completed study, sponsored by AdventHealth.
NCT03424382 is a clinical trial that has completed, run by AdventHealth. The registered enrollment target is 1,218 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03424382 has completed, sponsored by AdventHealth.
- COMPLETED
- Registry status
- 1,218 participants
- Enrollment target
Study Summary
This study occurs in two phases. Phase 1 involves initial item development and measurement validation of a new tool for identifying hospitalized patients at high risk for preventable readmission. Primary tasks include item construction and content validation, data collection, analysis, and instrument refinement. Phase 2 involves administering the refined instrument to a new group of patients to determine final item content for the instrument, its factor structure, and its predictive validity.
Primary Outcome
An Investigator developed measurement instrument (survey) will be used to gather participant self reported responses to questions regarding spirituality, nutrition, sleep, activity level, interpersonal relationships, home environment and access to transportation. Participants will be provided a five point Likert Scale to express agreement or disagreement with the questions.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,218 participants |
| Start Date | 2017-05-15 |
| Est. Completion | 2019-11-26 |
What the finished NCT03424382 record still lists
NCT03424382 is an observational study that tracks outcomes without assigning an intervention. Its 1,218 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT03424382 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03424382 about?
NCT03424382 is a clinical study titled "CREATION Health Readmission Risk Assessment Tool". This study occurs in two phases. Phase 1 involves initial item development and measurement validation of a new tool for identifying hospitalized patients at high risk for preventable readmission. Primary tasks include item construction and content validation, data collection, analysis, and instrumen...
What is the current status of trial NCT03424382?
This trial is currently completed. The enrollment target is 1,218 participants. The study started on 2017-05-15. Estimated completion is 2019-11-26.
Who is sponsoring clinical trial NCT03424382?
This trial is sponsored by AdventHealth, which has 95 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06143956 · 1,217 participants · Phase 2
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
- NCT06921785 · 1,220 participants · Phase 3
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
- NCT05827016 · 1,216 participants · Phase 3
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
- NCT04267848 · 1,210 participants · Phase 3
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI